Analyst Research Report Snapshot

Title:

FUTURA MEDICAL - CSD APPROVAL NEARS

Price:

$10.00

Provider:

Edison Investment Research

Date:

18 Mar 2008

Pages:

6

Type:

AcrobatPDF

Companies referenced:

FUM.L

Available for Immediate Download
Summary:

Despite an unexpectedly drawn-out regulatory process, a decision on Futura’s CSD500 condom at last looks imminent and, if approved, would make a commercial launch possible in the second half of this year. Meanwhile, GSK’s exclusivity on the TPR100 topical pain relief product finishes at the end of the month, representing a potential trigger for the long-awaited licensing deal. Futura is therefore in a relatively strong position with two potential value-enhancing events on the horizon. It is sufficiently well financed, especially if these events come to pass, to look at acquisition opportunities in the sector. FOR MORE INFORMATION ON ATTACHED RESEARCH PLEASE CALL 020 7190 1755 OR EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.